OS Therapies Inc (OSTX): Debts to Book Capitalization

Graphic logo of OS Therapies Inc. (OSTX)

OS Therapies Incorporated relies on a compact staff of scientists, outsourcing its research to external contractors. Efficient logistics for biologics ensure stable margins and supply reliability. The ratio of debt capital to the company's book capitalization on the GURU.Markets dynamic chart reflects a trend where the value of 0.00 serves as the baseline indicator. However, in the rare oncology niche, large pharma behemoths pose a serious threat, as they are capable of limiting the monopoly profits of small businesses.

OS Therapies Incorporated (OSTX) - Debts to Book Value from 08/02/2024 to 10/28/2026
Core merchandise of OS Therapies Inc.

This ratio determines the degree of the business's dependence on borrowed funds relative to its equity. Analyzing total debt against book capitalization allows for an assessment of financial stability and leverage levels. The metric is calculated as the ratio of all liabilities to the value of net assets. A decrease in this value confirms the autonomy of OS Therapies Incorporated (OSTX). The diversification of clinical trials minimizes risks, supporting capital stability during the development of targeted therapy.

Who OS Therapies Incorporated competes with

ONC - Debt to Book Capitalization Ratio|Debt to Book Value Ratio halozyme.com HALO|RVMD: Debts to Book Capitalization|AAPG - Debt to Book Value|Debts to Book Capitalization CGON|URGN (UroGen Pharma Corp) - Debts to Book Value|BCAX - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio personalis.com (PSNL)|Erasca (ERAS) - Debt to Book Value|Debt to Net Assets Ratio Delcath Systems Inc (DCTH)|YmAbs - Debts to Book Capitalization|AURA - Debt to Book Value|Candel - Debt to Book Value|ARAY: Debts to Book Capitalization|Debt to Book Capitalization Ratio sellaslifesciences.com SLS|Actuate Therapeutics Inc. (ACTU) - Debt to Net Assets Ratio|Debts to Book Capitalization CTOR (Citius Oncology, Inc)|Debts to Book Value HURA|Protara Therapeutics - Debt to Book Capitalization Ratio|Debts to Book Value FATE (fatetherapeutics.com)|Debt to Book Capitalization Ratio WHWK|TCRX - Debts to Net Assets|Debt to Book Value Champions Oncology Corp (CSBR)|XBiotech Inc. (XBIT) - Debt to Net Assets Ratio|CVM - Debt to Book Value|radiopharmtheranostics.com (RADX) - Debt to Book Capital|ARTV - Debts to Book Capitalization|Debt to Net Assets Ratio Adlai Nortye Limited|Veru Pharma - Debts to Book Capitalization|Debts to Book Value TPST (Tempest Therapeutics Corp)|Debt to Book Capitalization Ratio Xilio Therapeutics|Debt to Net Assets Ratio Renovaro Biosciences RENB|Mural Bio - Debts to Book Capitalization|KAPA: Debts to Book Capitalization|Debt to Book Capitalization Ratio onkuretherapeutics.com (OKUR)|CytoMed Therapeutics Limited (GDTC) - Debts to Book Capitalization Ratio|CRIS: Debts to Book Capitalization|Debts to Net Assets Apollomics Corp|Tharimmune - Debts to Book Capitalization|Debts to Book Value ADVB (advanbiomed.com)|Debt to Book Capitalization Ratio GNPX|CLDI - Debts to Net Assets|Debt to Book Value Sunshine Biopharma, Inc. (SBFM)|XBIO - Debt to Net Assets Ratio|Salarius Pharmaceuticals, Inc. - Debts to Book Capitalization|PPBT (Purple Biotech Ltd) - Debts to Net Assets|Debt to Book Capitalization Ratio American Oncology Network Inc (AONC)|Debt to Book Value Ratio BeiGene Ltd|Debts to Book Capitalization CKPT (Checkpoint Therapeutics)|Debt to Book Value ELEV (elevationoncology.com)|ICAD: Debt to Book Capitalization Ratio|Ikena Oncology Inc. - Debts to Book Value|Debt to Book Capitalization Ratio Notable Labs Inc. (NTBL)|VIRX: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio MorphoSys AG (MOR)|NAYA (nayabiosciences.com) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio AAPGV (Ascentage Pharma)